Novel tissue-agnostic biomarker approaches could improve response to immunotherapy
Several studies describe pan-cancer approaches utilising the latest technology for better patient selection and outcomes
New artificial intelligence-based biomarkers offer early insight into treatment response
Findings from four studies provide further evidence on the potential of AI-driven pathology, imaging and multiomic data to guide clinical decision-making
Innovative strategies lead to mixed benefits for rare cancers
Positive findings are presented for advanced Merkel-cell carcinoma plus phaeochromocytoma and paragangliomas, while negative findings are equally important to guide future research
New directions in metastatic mutated NSCLC
Precision targeting, immune modulation and rational trial design are converging to improve patient outcomes
Sustained benefits of neoadjuvant immunotherapy demonstrated in resectable melanoma
Longer follow-up from two studies supports neoadjuvant over adjuvant immune checkpoint inhibition in patients with resectable melanoma and clinically or radiologically detectable metastasis, plus useful insights gained from biomarker analyses will help refine treatment strategies
Study presents an AI-guided approach to target cancer antigens
The innovative approach was successfully tested on NY-ESO-1 and promises to bypass some current challenges in the identification of T cell receptors for therapeutic use
Immune interception represents an exciting opportunity to stop cancer in its tracks
Data from two studies suggest a good rationale for targeting T-cell dysfunction with precision immunotherapy to intercept pre-cancerous lesions
Are we close to personalise immunotherapy?
According to the 2024 ESMO Immuno-Oncology Awardee, Ton Schumacher, tackling the T-cell receptor challenge with vast datasets and cutting-edge high-throughput methods may pave the way for advances in the field
Tumour-agnostic oncology – time has come to re-think clinical research
Advances in precision oncology are moving the field towards a biology-based cancer care, and ESMO is supporting the change with a series of tailored resources for medical oncologists
Challenges in cell-based immunotherapies create opportunities for progress
According to the 2023 ESMO Immuno-Oncology Awardee, Steven A. Rosenberg, the keys to progress are identifying the optimal characteristics of antitumour effector lymphocytes, cancer antigen identification and strategies for overcoming resistance mechanisms to enhance immune-cell function